Daily Scoop🍨: Genprex (GNPX) Earnings Strong Buy 🙏💪🔥
Genprex Inc GNPX.OQ reported a quarterly adjusted loss of $1.23 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of two analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-2.73 to $-1.13 per share.
Reported revenue was expected !
Genprex Inc's reported EPS for the quarter was a loss of $1.23.
The company reported a quarterly loss of $4.32 million.
Genprex Inc shares had risen by 477.8% this quarter and lost 77.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Genprex Inc is 8.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
